Sanofi: Sanofi Earnings: Solid Dupixent Growth Offsets Mature Drug Declines and Generic Pressures

Symbols

SNY

Sector(s)

Healthcare

Rating

Current Price

$50.80

Fair Value

Economic Moat

Stewardship

Summary

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Subscribe to Yahoo Finance Plus Essential for full access

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Try it Free

Actions

Download Full Report

Related Reports

View more related reports

Analyst Profile

Damien Conover

Sector Director

Damien Conover, CFA, is director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar's investment philosophy by working closely with the firm's North American sector strategists and directors.Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.Conover holds bachelor's and master's degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.